In:
Intervirology, S. Karger AG, Vol. 50, No. 4 ( 2007), p. 296-302
Kurzfassung:
〈 i 〉 Objectives: 〈 /i 〉 The objectives of the study were to evaluate the safety and antiviral activity of 24-week treatment with clevudine 30 mg in HBeAg(+) chronic hepatitis B patients. Biochemical and serological responses were also assessed. 〈 i 〉 Method: 〈 /i 〉 Twenty-one patients received clevudine 30 mg for 24 weeks and were followed up for another 24 weeks off therapy. 〈 i 〉 Results: 〈 /i 〉 Median decreases from baseline in HBV DNA were 4.65 and 1.96 log 〈 sub 〉 10 〈 /sub 〉 copies/ml at week 24 (end of treatment) and week 48 (24 weeks off therapy), respectively. Analysis of individual data showed that HBV DNA levels were below the lower limit of detection (300 copies/ml) by Amplicor PCR assay in 19, 57, 19 and 0% at week 12, 24, 34 and 48, respectively. The proportion of patients with normal ALT were 67, 81 and 75% at week 24 (end of treatment), 34 and 48 (24 weeks off therapy), respectively. The rates of HBeAg loss were 24 and 20% at week 24 and 48, respectively. No viral breakthrough during treatment was observed. 〈 i 〉 Conclusion: 〈 /i 〉 Clevudine 30 mg treatment for 24 weeks was well tolerated and exhibited more potent antiviral activity and a higher ALT normalization rate than 12-week treatment with durable efficacy at week 24 off therapy.
Materialart:
Online-Ressource
ISSN:
0300-5526
,
1423-0100
Sprache:
Englisch
Verlag:
S. Karger AG
Publikationsdatum:
2007
ZDB Id:
1482863-7
SSG:
12
